The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reshaping the small-cap biotech landscape, Passage Bio (PASG) announced a definitive all-stock merger agreement with Remix Therapeutics. Under the terms, Passage Bio shareholders will own only about 7% of the combined company, which will focus on advancing the lead program REM-422 targeting MYB in cancers such as adenoid cystic carcinoma and acute myeloid leukemia, according to reports.
The deal includes an oversubscribed private placement of approximately $100 million that will fund operations into 2028, providing a cash runway for the lead program. The move comes amid growing investor interest in RNA-based therapeutics, though small companies face regulatory and commercial hurdles. Market data shows PASG closed at $5.59 on June 18, 2026, with an intraday range of $5.27 to $5.65.
Investors are now focused on the combined entity's ability to achieve clinical milestones for REM-422, especially amid rising competition in genetically targeted cancer therapies. The stock may need further catalysts from Phase I results or strategic partnerships to reverse its current bearish trend, as the low ownership stake reflects limited confidence in the standalone company.